Pharmacological inhibition of coronary restenosis: Systemic and local approaches

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 15, 2014, Pages 2155-2171

  Guerra, Elena ^a   Byrne, Robert A ^a   Kastrati, Adnan ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Cilostazol; Drug eluting balloon; Oral sirolimus; Probucol; Restenosis; Stent; Tranilast

Indexed keywords

ANTIINFLAMMATORY AGENT; CILOSTAZOL; COLCHICINE; EVEROLIMUS; PACLITAXEL; PIOGLITAZONE; PREDNISONE; PROBUCOL; RAPAMYCIN; TRANILAST; UMIROLIMUS; ZOTAROLIMUS; ANTHRANILIC ACID DERIVATIVE; ANTIINFECTIVE AGENT; ANTIOXIDANT; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; TETRAZOLE DERIVATIVE; TUBULIN MODULATOR; VASODILATOR AGENT;

CELL PROLIFERATION; CORONARY ARTERY DISEASE; CORONARY STENT; DEVICE FAILURE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG ELUTING STENT; DRUG STRUCTURE; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; IN-STENT RESTENOSIS; MEDICAL DEVICE COMPLICATION; MUSCLE CELL; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; CHEMISTRY; DRUG ELUTING BALLOON; ORAL SIROLIMUS; RESTENOSIS; STENT;

CILOSTAZOL; DRUG ELUTING BALLOON; ORAL SIROLIMUS; PROBUCOL; RESTENOSIS; STENT; TRANILAST;

ANTI-BACTERIAL AGENTS; ANTIOXIDANTS; CORONARY RESTENOSIS; DRUG DELIVERY SYSTEMS; DRUG-ELUTING STENTS; HUMANS; ORTHO-AMINOBENZOATES; PACLITAXEL; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROBUCOL; SIROLIMUS; TETRAZOLES; TUBULIN MODULATORS; VASODILATOR AGENTS;

EID: 84907279889     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.948844     Document Type: Review

References (132)

1. Marcus AJ. Thrombosis and inflammation as multicellular processes: significance of cell-cell interactions. Semin Hematol 1994;31:261-9
2. Simon DI. Inflammation and vascular injury: basic discovery to drug development. Circ J 2012;76:1811-18
3. Forrester JS, Fishbein M, Helfant R, et al. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69
4. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation 2001;103:1718-20
5. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331:489-95
6. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331:496-501
7. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002;22:1769-76
8. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of instent restenosis. A serial intravascular ultrasound study. Circulation 1996;94:1247-54
9. Rogers C, Edelman ER, Simon DI. A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci USA 1998;95:10134-9
10. Libby P, Schwartz D, Brogi E, et al. A cascade model for restenosis. A special case of atherosclerosis progression. Circulation 1992;86:III47-52
11. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-23
12. Byrne RA, Iijima R, Mehilli J, et al. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2009;2:291-9
13. Kimura T, Yokoi H, Nakagawa Y, et al. Three-year follow-up after implantation of metallic coronary-artery stents. N Engl J Med 1996;334:561-6
14. Schomig A, Kastrati A, Wessely R. Prevention of restenosis by systemic drug therapy: back to the future? Circulation 2005;112:2759-61
15. Peters S. Can angiotensin receptor antagonists prevent restenosis after stent placement? Am J Cardiovasc Drugs 2002;2:143-8
16. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003;92:1049-55
17. Miller JL. Sirolimus approved with renal transplant indication. Am J Health Syst Pharm 1999;56:2177-8
18. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003;108:48-53
19. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004;110:2694-700
20. Braun-Dullaeus RC, Mann MJ, Dzau VJ. Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 1998;98:82-9
21. Marx SO, Jayaraman T, Go LO, et al. Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells. Circ Res 1995;76:412-17
22. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation 2001;104:852-5
23. Sabatini DM, Erdjument-Bromage H, Lui M, et al. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 1994;78:35-43
24. Martin KA, Rzucidlo EM, Merenick BL, et al. The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation. Am J Physiol Cell Physiol 2004;286:C507-17
25. Poon M, Marx SO, Gallo R, et al. Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest 1996;98:2277-83
26. Kahan BD, Wong RL, Carter C, et al. A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1999;68:1100-6
27. Nashan B. The role of Certican (everolimus, rad) in the many pathways of chronic rejection. Transplant Proc 2001;33:3215-20
28. Garcia-Touchard A, Burke SE, Toner JL, et al. Zotarolimus-eluting stents reduce experimental coronary artery neointimal hyperplasia after 4 weeks. Eur Heart J 2006;27:988-93
29. Collingwood R, Gibson L, Sedlik S, et al. Stent-based delivery of ABT-578 via a phosphorylcholine surface coating reduces neointimal formation in the porcine coronary model. Catheter Cardiovasc Interv 2005;65:227-32
30. Grube E, Buellesfeld L. BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. Expert Rev Med Devices 2006;3:731-41
31. Costa JR Jr, Abizaid A, Feres F, et al. EXCELLA First-in-Man (FIM) study: safety and efficacy of novolimus-eluting stent in de novo coronary lesions. EuroIntervention 2008;4:53-8
32. Jun CD, Choi BM, Kim HM, et al. Involvement of protein kinase C during taxol-induced activation of murine peritoneal macrophages. J Immunol 1995;154:6541-7
33. Manthey CL, Perera PY, Salkowski CA, et al. Taxol provides a second signal for murine macrophage tumoricidal activity. J Immunol 1994;152:825-31
34. Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J Immunol 1999;162:6811-18
35. Mullins DW, Walker TM, Burger CJ, et al. Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities. Cancer Immunol Immunother 1997;45:20-8
36. Morishita R. A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis. Atheroscler Suppl 2005;6:41-6
37. Inoue T, Uchida T, Sakuma M, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation. J Am Coll Cardiol 2004;44:1408-14
38. Ferns GA, Forster L, Stewart-Lee A, et al. Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis 1993;100:171-81
39. Wu BJ, Kathir K, Witting PK, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 2006;203:1117-27
40. Reinoehl J, Frankovich D, Machado C, et al. Probucol-associated tachyarrhythmic events and QT prolongation: importance of gender. Am Heart J 1996;131:1184-91
41. Hirano K, Ikegami C, Tsujii K, et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol 2005;25:2422-7
42. Komatsu H, Kojima M, Tsutsumi N, et al. Study of the mechanism of inhibitory action of tranilast on chemical mediator release. Jpn J Pharmacol 1988;46:43-51
43. Kawano Y, Noma T. Cell action mechanism of tranilast-effect on the expression of HLA-class II antigen. Int J Immunopharmacol 1993;15:487-500
44. Michalik L, Auwerx J, Berger JP, et al. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev 2006;58:726-41
45. Marx N, Duez H, Fruchart JC, et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 2004;94:1168-78
46. Kasai T, Miyauchi K, Yokoyama T, et al. Pioglitazone attenuates neointimal thickening via suppression of the early inflammatory response in a porcine coronary after stenting. Atherosclerosis 2008;197:612-19
47. Igarashi M, Hirata A, Yamaguchi H, et al. Characterization of an inhibitory effect of pioglitazone on balloon-injured vascular smooth muscle cell growth. Metabolism 2001;50:955-62
48. Takagi T, Yoshida K, Akasaka T, et al. Hyperinsulinemia during oral glucose tolerance test is associated with increased neointimal tissue proliferation after coronary stent implantation in nondiabetic patients: a serial intravascular ultrasound study. J Am Coll Cardiol 2000;36:731-8
49. Sabate M, Cequier A, Iniguez A, et al. Everolimus-eluting stent versus baremetal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. Lancet 2012;380:1482-90
50. Byrne RA, Joner M, Tada T, et al. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. Minerva Cardioangiol 2012;60:473-89
51. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA 2005;294:1215-23
52. Tanner FC, Boehm M, Akyurek LM, et al. Differential effects of the cyclindependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation. Circulation 2000;101:2022-5
53. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-95
54. Levin AD, Vukmirovic N, Hwang CW, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc Natl Acad Sci USA 2004;101:9463-7
55. Hwang CW, Levin AD, Jonas M, et al. Thrombosis modulates arterial drug distribution for drug-eluting stents. Circulation 2005;111:1619-26
56. Wessely R, Kastrati A, Mehilli J, et al. Randomized trial of rapamycin- and paclitaxel-eluting stents with identical biodegradable polymeric coating and design. Eur Heart J 2007;28:2720-5
57. Serruys PW, Sianos G, Abizaid A, et al. The effect of variable dose and release kinetics on neointimal hyperplasia using a novel paclitaxel-eluting stent platform: the Paclitaxel In-Stent Controlled Elution Study (PISCES). J Am Coll Cardiol 2005;46:253-60
58. Steigerwald K, Ballke S, Quee SC, et al. Vascular healing in drug-eluting stents: differential drug-associated response of limus-eluting stents in a preclinical model of stent implantation. EuroIntervention 2012;8:752-9
59. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drugeluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115:2435-41
60. von Birgelen C, Basalus MW, Tandjung K, et al. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial. J Am Coll Cardiol 2012;59:1350-61
61. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012;379:1393-402
62. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52:333-42
63. Sousa JE, Costa MA, Abizaid A, et al. Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents. Circulation 2005;111:2326-9
64. Kastrati A, Mehilli J, Dirschinger J, et al. Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation 2001;103:2816-21
65. Kolandaivelu K, Swaminathan R, Gibson WJ, et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011;123:1400-9
66. Otsuka F, Vorpahl M, Nakano M, et al. Pathology of second-generation everolimus-eluting stents versus firstgeneration sirolimus- and paclitaxeleluting stents in humans. Circulation 2014;129:211-23
67. Byrne RA, Joner M, Alfonso F, et al. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol 2014;11:13-23
68. Scheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006;355:2113-24
69. Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. Clin Res Cardiol 2008;97:773-81
70. Habara S, Iwabuchi M, Inoue N, et al. A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosis. Am Heart J 2013;166:527-33
71. Unverdorben M, Vallbracht C, Cremers B, et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary instent restenosis. Circulation 2009;119:2986-94
72. Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting balloons, paclitaxeleluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet 2013;381:461-7
73. Cortese B, Micheli A, Picchi A, et al. Paclitaxel-coated balloon versus drugeluting stent during PCI of small coronary vessels, a prospective randomised clinical trial. The PICCOLETO study. Heart 2010;96:1291-6
74. Latib A, Colombo A, Castriota F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am Coll Cardiol 2012;60:2473-80
75. Stella PR, Belkacemi A, Dubois C, et al. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drugeluting stent in bifurcation lesions treated with a single-stenting technique: sixmonth angiographic and 12-month clinical results of the drug-eluting balloon in bifurcations trial. Catheter Cardiovasc Interv 2012;80:1138-46
76. Lemos PA, Farooq V, Takimura CK, et al. Emerging technologies: polymerfree phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. EuroIntervention 2013;9:148-56
77. Gallo R, Padurean A, Jayaraman T, et al. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. Circulation 1999;99:2164-70
78. Burke SE, Lubbers NL, Chen YW, et al. Neointimal formation after ballooninduced vascular injury in Yucatan minipigs is reduced by oral rapamycin. J Cardiovasc Pharmacol 1999;33:829-35
79. Waksman R, Ajani AE, Pichard AD, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study. J Am Coll Cardiol 2004;44:1386-92
80. Rodriguez AE, Rodriguez Alemparte M, Vigo CF, et al. Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial). Heart 2005;91:1433-7
81. Rodriguez AE, Granada JF, Rodriguez-Alemparte M, et al. Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study. J Am Coll Cardiol 2006;47:1522-9
82. Hausleiter J, Kastrati A, Mehilli J, et al. Randomized, double-blind, placebocontrolled trial of oral sirolimus for restenosis prevention in patients with instent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial. Circulation 2004;110:790-5
83. Kufner S, Hausleiter J, Ndrepepa G, et al. Long-term risk of adverse outcomes and new malignancies in patients treated with oral sirolimus for prevention of restenosis. JACC Cardiovasc Interv 2009;2:1142-8
84. Rodriguez AE, Palacios I, Rodriguez-Granillo AM, et al. Comparison of cost-effectiveness of oral rapamycin plus bare-metal stents versus first generation of drug-eluting stents (from the Randomized Oral Rapamycin in Argentina [ORAR] 3 trial). Am J Cardiol 2014;113:815-21
85. Rodriguez AE, Rodriguez-Granillo AM, Antoniucci D, et al. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus baremetal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial. Catheter Cardiovasc Interv 2012;80:385-94
86. Schampaert E, Cohen EA, Schluter M, et al. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (CSIRIUS). J Am Coll Cardiol 2004;43:1110-15
87. Schofer J, Schluter M, Gershlick AH, et al. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS). Lancet 2003;362:1093-9
88. Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation 2012;126:1225-36
89. Dasari TW, Patel B, Saucedo JF. Systematic review of effectiveness of oral sirolimus after bare-metal stenting of coronary arteries for prevention of instent restenosis. Am J Cardiol 2013;112:1322-7
90. Tsuchikane E, Fukuhara A, Kobayashi T, et al. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999;100:21-6
91. Nagaoka N, Matsubara T, Okazaki K, et al. Comparison of ticlopidine and cilostazol for the prevention of restenosis after percutaneous transluminal coronary angioplasty. Jpn Heart J 2001;42:43-54
92. Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, et al. Coronary stent restenosis in patients treated with cilostazol. Circulation 2005;112:2826-32
93. Lee SW, Park SW, Kim YH, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients). J Am Coll Cardiol 2008;51:1181-7
94. Lee SW, Park SW, Kim YH, et al. Comparison of triple versus dual antiplatelet therapy after drug-eluting stent implantation (from the DECLARELong trial). Am J Cardiol 2007;100:1103-8
95. Tamhane U, Meier P, Chetcuti S, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a metaanalysis of randomised controlled trials. EuroIntervention 2009;5:384-93
96. Park KW, Kang SH, Park JJ, et al. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen). JACC Cardiovasc Interv 2013;6:932-42
97. Ahn Y, Jeong MH, Jeong JW, et al. Randomized comparison of cilostazol vs clopidogrel after drug-eluting stenting in diabetic patients-clilostazol for diabetic patients in drug-eluting stent (CIDES) trial. Circ J 2008;72:35-9
98. Lee SW, Lee JY, Ahn JM, et al. Comparison of dual versus triple antiplatelet therapy after drug-eluting stent according to stent length (from the pooled analysis of DECLARE trials). Am J Cardiol 2013;112:1738-44
99. Tardif JC, Cote G, Lesperance J, et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group. N Engl J Med 1997;337:365-72
100. Yokoi H, Daida H, Kuwabara Y, et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial. J Am Coll Cardiol 1997;30:855-62
101. O'Keefe JH Jr, Stone GW, McCallister BD Jr, et al. Lovastatin plus probucol for prevention of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1996;77:649-52
102. Tardif JC, McMurray JJ, Klug E, et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebocontrolled trial. Lancet 2008;371:1761-8
103. Tardif JC, Gregoire J, Schwartz L, et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003;107:552-8
104. Nunes GL, Abizaid AC, Theodoro MP, et al. Role of probucol in inhibiting intimal hyperplasia after coronary stent implantation: a randomized study. Am Heart J 2006;152:914.e1-7
105. Cote G, Tardif JC, Lesperance J, et al. Effects of probucol on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation 1999;99:30-5
106. Tardif JC, Gregoire J, Lavoie MA, et al. Pharmacologic prevention of both restenosis and atherosclerosis progression: AGI-1067, probucol, statins, folic acid and other therapies. Curr Opin Lipidol 2003;14:615-20
107. Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study. Circulation 1997;95:1366-9
108. Takagi T, Yamamuro A, Tamita K, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003;146:E5
109. Takagi T, Okura H, Kobayashi Y, et al. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv 2009;2:524-31
110. Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006;29:101-6
111. Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005;112:2792-8
112. Katayama T, Ueba H, Tsuboi K, et al. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 2007;153:762.e1-7
113. Kaneda H, Shiono T, Miyashita Y, et al. Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation. Heart 2009;95:1079-84
114. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003;108:2941-8
115. Erdmann E, Charbonnel B, Wilcox RG, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care 2007;30:2773-8
116. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 2005;294:2581-6
117. Schwartz AV. TZDs and bone: a review of the recent clinical evidence. PPAR Res 2008;2008:297893
118. Takahashi A, Taniguchi T, Ishikawa Y, et al. Tranilast inhibits vascular smooth muscle cell growth and intimal hyperplasia by induction of p21 (waf1/cip1/sdi1) and p53. Circ Res 1999;84:543-50
119. Tamai H, Katoh O, Suzuki S, et al. Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am Heart J 1999;138:968-75
120. Tamai H, Katoh K, Yamaguchi T, et al. The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J 2002;143:506-13
121. Holmes DR Jr, Savage M, LaBlanche JM, et al. Results of prevention of REStenosis with tranilast and its outcomes (PRESTO) trial. Circulation 2002;106:1243-50
122. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive therapy for the prevention of restenosis after coronary artery stent implantation (IMPRESS Study). J Am Coll Cardiol 2002;40:1935-42
123. Ribichini F, Tomai F, Pesarini G, et al. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). Eur Heart J 2013;34:1740-8
124. Imazio M, Brucato A, Adler Y. A randomized trial of colchicine for acute pericarditis. N Engl J Med 2014;370:781
125. Molad Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep 2002;4:252-6
126. Freed M, Safian RD, O'Neill WW, et al. Combination of lovastatin, enalapril, and colchicine does not prevent restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1995;76:1185-8
127. O'Keefe JH Jr, McCallister BD, Bateman TM, et al. Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol 1992;19:1597-600
128. Deftereos S, Giannopoulos G, Raisakis K, et al. Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol 2013;61:1679-85
129. Cernigliaro C, Sansa M, Vitrella G, et al. Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5- year clinical follow-up. Cardiology 2010;115:77-86
130. Stojkovic S, Ostojic M, Nedeljkovic M, et al. Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation. Catheter Cardiovasc Interv 2010;75:317-25
131. Jeong JW SD, Moon JY, Yoon NS, et al. The Effects of Cilostazol on 6-Month Angiographic and 1-Year Clinical Outcomes in Patients with Diabetes Who Underwent Drug-Eluting Stent Implantation. America Journal of Cardiology 2008;101:S1-S108
132. Hong SJ PC, Choi JI, Shim WJ, et al. Effects of Cilostazol on Carotid Intima- Media Thickness in Patients with Acute Coronary Syndrome. America Journal of Cardiology 2008;101:S1-S108